Form 4: Xenon Pharmaceuticals Inc. Executive Acquires Shares and Options

Andrea DiFabio, Chief Legal Officer of Xenon Pharmaceuticals, reports acquisition of share options and restricted share units.

Summary

• Andrea DiFabio, Chief Legal Officer of Xenon Pharmaceuticals Inc., filed a Form 4 detailing changes in beneficial ownership.
• The report indicates the acquisition of 80,000 share options with an exercise price of $35.48, vesting 25% on March 12, 2026, and the remainder over the following three years.
• DiFabio also acquired 15,000 restricted share units, vesting 25% annually starting March 12, 2026.
• Both the share options and restricted share units are directly owned.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of executive compensation. The acquisition of shares and options could be seen as a positive sign, but it's not necessarily indicative of a major shift in the company's outlook.

Positives

• The acquisition of share options and restricted share units by a key executive could signal confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted share units to align management's interests with those of shareholders.
• Vesting schedules are typical, designed to incentivize long-term commitment and performance.
• The specific terms of these grants (exercise price, vesting schedule) are company-specific and depend on factors such as company size, industry, and individual performance.

Stakeholder Impact

• The acquisition of share options and restricted share units by a key executive could positively influence shareholder sentiment.

Key Dates